Drug Profile
Research programme: mucosal vaccines - Mucosis
Alternative Names: Hepatitis B vaccine - Mucosis; Malaria vaccine - Mucosis; Plague vaccine - Mucosis; PneuGEM; Shigella and other enteric bacterial pathogens vaccines - Mucosis; Yersinia pestis vaccine - MucosisLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Mucosis; Virtuvax
- Developer Mucosis; University of Copenhagen
- Class Antibodies; Bacterial vaccines; Glycoproteins; Hepatitis B vaccines; Membrane fusion proteins; Parasitic vaccines; Pneumococcal vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis B; Malaria; Otitis media; Pneumococcal infections; Pneumonia; Respiratory syncytial virus infections; Shigella infections; Yersinia infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections(Prevention) in Netherlands (Intranasal, Drops)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Malaria(Prevention) in Netherlands (Intranasal)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pneumococcal-infections(Prevention) in Netherlands (Intranasal)